United States Neurological Diagnostic and Monitoring Equipment Market Outlook to 2033 - Electrical Activity Testing and ICP Monitoring Devices

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 What Is This Report About?
• 2.2 Neurological Diagnostic and Monitoring Equipment Devices Market Segmentation
• 2.3 Definitions of Markets Covered in the Report

3 Neurological Diagnostic and Monitoring Equipment Market, United States

• 3.1 Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), 2018-2033
  • 3.1.1 Electrical Activity Testing Market, United States, Revenue ($m), by Segment, 2018-2033
  • 3.1.2 ICP Monitoring Devices Market, United States, Revenue ($m), by Segment, 2018-2033
• 3.2 Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
  • 3.2.1 Electrical Activity Testing Market, United States, Volume (Units), by Segment, 2018-2033
  • 3.2.2 ICP Monitoring Devices Market, United States, Volume (Units), by Segment, 2018-2033
• 3.3 Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033
• 3.4 Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025

4 Overview of Key Companies in United States, Neurological Diagnostic and Monitoring Equipment Market

• 4.1 Natus Medical Inc
  • 4.1.1 Company Overview
• 4.2 Nihon Kohden Corp
  • 4.2.1 Company Overview
• 4.3 Medtronic Plc
  • 4.3.1 Company Overview
• 4.4 Masimo Corp
  • 4.4.1 Company Overview
• 4.5 Cadwell Industries Inc
  • 4.5.1 Company Overview
• 4.6 Integra LifeSciences Corp
  • 4.6.1 Company Overview
• 4.7 Compumedics Ltd
  • 4.7.1 Company Overview
• 4.8 Megin Oy
  • 4.8.1 Company Overview
• 4.9 ANT Neuro BV
  • 4.9.1 Company Overview

5 Neurological Diagnostic and Monitoring Equipment Market Pipeline Products

6 Recent Developments

• 6.1 Corporate Communications
  • 6.1.1 Jan 08, 2026: Natus Sensory Appoints Arne Boye Nielsen to Board of Directors
  • 6.1.2 Nov 21, 2025: Stroke Prevention Study CREST-2 Stenting
  • 6.1.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson's Disease
  • 6.1.4 Nov 19, 2025: Renowned Neuromuscular Expert to Lead New NYU Langone ALS Center
  • 6.1.5 Nov 05, 2025: Genesys Strike Negotiations Update
  • 6.1.6 Nov 05, 2025: W&L Expands Parental Leave Benefits for Faculty and Staff
  • 6.1.7 Nov 04, 2025: BrainScope Appoints Matt Adams as Chief Executive Officer
  • 6.1.8 Oct 30, 2025: End Brain Cancer Initiative Partners with Exvade Bioscience to Raise Awareness of Brain Cancer Study
  • 6.1.9 Oct 30, 2025: Siddiqui Performs World's First Robotic Microsurgical Intracranial Brain Surgery
  • 6.1.10 Oct 24, 2025: Payman Khales Becomes Integer President and CEO
  • 6.1.11 Oct 21, 2025: Laura Jane Ramsburg Appointed Director of Staniar Gallery
  • 6.1.12 Oct 17, 2025: W&L Welcomes New Trustees Thomas J. Sheehan and Andrew W. Tate
  • 6.1.13 Oct 07, 2025: Altoida Expands Advisory Board with Global Leaders in AI, Pharma, and Alzheimer's Advocacy
  • 6.1.14 Oct 01, 2025: College of Nursing and Public Health Advisory Board Welcomes Marc Adler and Jennifer McIntosh
  • 6.1.15 Sep 24, 2025: CWSL Alumna Sherry S. Bahrambeygui Elected to UC San Diego Foundation Board
  • 6.1.16 Sep 12, 2025: Christina J. Yang, MD, Joins Hassenfeld Children's Hospital as Chief of Pediatric Otolaryngology
  • 6.1.17 Sep 12, 2025: Renowned Specialist to Lead New Dry Eye Service at NYU Langone Eye Center
  • 6.1.18 Sep 08, 2025: UC San Diego Foundation Announces New Trustees
  • 6.1.19 May 16, 2025: Magstim Granted EU MDR Certification
• 6.2 Financial Announcements
  • 6.2.1 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
  • 6.2.2 May 05, 2025: Integra LifeSciences Reports First Quarter 2025 Financial Results
  • 6.2.3 Apr 18, 2025: Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025
  • 6.2.4 Apr 17, 2025: GE HealthCare to Announce First Quarter 2025 Results on April 30, 2025
  • 6.2.5 Feb 04, 2025: Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
• 6.3 Government and Public Interest
  • 6.3.1 Dec 01, 2025: Integra LifeSciences Leadership to Present at Citi 2025 Global Healthcare Conference
  • 6.3.2 Nov 17, 2025: GE HealthCare Management to Present at Upcoming Investor Conference
  • 6.3.3 Oct 29, 2025: Seer to Participate in Upcoming November Investor Conferences
  • 6.3.4 Sep 25, 2025: Integer Announces Conference Call to Discuss Third Quarter 2025 Results
  • 6.3.5 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
  • 6.3.6 Aug 29, 2025: Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
  • 6.3.7 Aug 21, 2025: GE HealthCare Management to Present at Upcoming Investor Conferences
  • 6.3.8 Aug 12, 2025: Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4
  • 6.3.9 Feb 10, 2025: GE Healthcare Management to Present at Upcoming Investor Conference
• 6.4 Other Significant Developments
  • 6.4.1 Nov 24, 2025: NeuroPace Announces Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
  • 6.4.2 Nov 10, 2025: Hope Therapeutics, Inc. Announces First-in-Florida Initiation of One Day Depression Treatment
  • 6.4.3 Oct 24, 2025: Laser Procedure Offers Solutions For Epilepsy And Brain Tumors
  • 6.4.4 Jun 02, 2025: Listening to Lives Behind the Numbers: Linus Health Study Champions Person-Centered Brain Health Assessments
• 6.5 Product News
  • 6.5.1 Jan 14, 2026: Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting
  • 6.5.2 Nov 26, 2025: Neuro Event Labs Receives FDA 510(k) Clearance for Nelli Seizure Monitoring System
  • 6.5.3 Nov 20, 2025: PhotoPharmics Exceeds Enrollment Goal with 350 Participants in Remote Phase 3 Clinical Trial for Parkinson's Disease
  • 6.5.4 Nov 18, 2025: QuantalX Receives FDA De Novo Clearance for Delphi-MD
  • 6.5.5 Nov 15, 2025: Evidence Builds for Disrupted Mitochondria as Cause of Parkinson's
  • 6.5.6 Nov 10, 2025: URI Team Develops Tabletop Device to Study Long-Term Effects of Traumatic Brain Injury
  • 6.5.7 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer's Patients
  • 6.5.8 Oct 30, 2025: Siddiqui Performs World's First Robotic Microsurgical Intracranial Brain Surgery
  • 6.5.9 Oct 29, 2025: FDA-Approved Focused Ultrasound Treatment for Essential Tremor Now Used for Parkinson's
  • 6.5.10 Oct 21, 2025: Nexalin's DIFS Neurostimulation Demonstrates Cognitive Improvements in Alzheimer's and Dementia
  • 6.5.11 Oct 20, 2025: Neupulse Partnership Introduces Innovative Wearable for Tourette Syndrome
  • 6.5.12 Oct 15, 2025: XRHealth Receives U.S. Patent for Advanced XR System Measuring Upper-Limb Impairments
  • 6.5.13 Oct 07, 2025: Brain Stimulation May Reduce Cannabis Addiction in People with Multiple Sclerosis
  • 6.5.14 Sep 24, 2025: Eysz Announces Positive Results of NIH-Funded Study on Novel Absence Seizure Screening Tool
  • 6.5.15 Sep 23, 2025: FDA Clears Cionic Neural Sleeve 2 For Enhanced Mobility Care
  • 6.5.16 Jul 28, 2025: Anywhere powered by Linus Health Expands Equitable Access to Early Detection of Cognitive Impairment
  • 6.5.17 Mar 18, 2025: Anywhere for Health Systems Delivers Clinical-Grade Cognitive Assessments Remotely

7 Appendix

• 7.1 Research Methodology
  • 7.1.1 Coverage
  • 7.1.2 Secondary Research
  • 7.1.3 Primary Research
  • 7.1.4 Market Modeling and Forecasting
  • 7.1.5 Company Share Analysis
  • 7.1.6 Benchmarking
• 7.2 GlobalData Consulting
• 7.3 Contact Us
• 7.4 Disclaimer

List of Table

List of Tables

• Table 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033
• Table 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033
• Table 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Table 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
• Table 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033
• Table 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033
• Table 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Average Price ($), 2018-2033
• Table 8: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share by Revenue ($m), 2025
• Table 9: Neurological Diagnostic and Monitoring Equipment Market Pipeline Products
• Table 10: Total Number of Primary Research Participants, Neurology Devices Market, by Country

List of Figure

List of Figures

• Figure 1: Neurological Diagnostic and Monitoring Equipment Market, United States, Revenue ($m), USD Constant, 2018-2033
• Figure 2: Electrical Activity Testing Market, United States, Revenue ($m), USD Constant, 2018-2033
• Figure 3: ICP Monitoring Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
• Figure 4: Neurological Diagnostic and Monitoring Equipment Market, United States, Volume (Units), 2018-2033
• Figure 5: Electrical Activity Testing Market, United States, Volume (Units), 2018-2033
• Figure 6: ICP Monitoring Devices Market, United States, Volume (Units), 2018-2033
• Figure 7: Neurological Diagnostic and Monitoring Equipment Market, United States, Company Share (%), 2025